



23rd June, 2016

Mr. Avishkar Naik, Chief Manager
Surveillance
National Stock Exchange of India Ltd.
Exchange Plaza, Plot No.C/1
G-Block, Bandra-kurla Complex,
Bandra (E), MUMBAI – 400 051.

Dear Sir,

Sub: confirmation / information on public news –reg.
Ref: Your letter no.NSE/CM/Surveillance / 6305 dt.23-06-2016

With reference to your above letter, we wish to inform you the following:

We received from our US agent on 22nd June 2016 intimating the approval for generic version of Glycopyrrolate Tablets 1mg and 2mg from US FDA (Reference Listed Drug (RLD) is Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, of Casper Pharma LLC). We have not disclosed the said news to any agency / institution / person. The news captioned by CNBC TV18 “NATCO PHARMA gets USFDA nod for Glycopyrrolate drug” was probably obtained by the said agency from their own sources.

Glycopyrrolate will be manufactured at our Finished Dosage Facility located at Kothur, near Hyderabad, India.

The market potential of the product is not significant. The Company believes the product will not have any material or financial impact on its operations.

This is for your information.

Thanking you

Yours faithfully,
For NATCO Pharma Limited

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)